All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Chemocentryx Inc. has divulged azetidinyl-acetamides acting as atypical chemokine receptor 3 (ACKR3) antagonists reported to be useful for the treatment of cancer and inflammatory disorders.
